



OFFICE OF NAVAL RESEARCH

Contract N00014-76-C-0229

Project NR 105-516

TECHNICAL REPORT NO. 124

INCREASED SURVIVAL WITH METHYLPREDNISOLONE
POST-TREATMENT IN LETHAL ENDOTOXIN SHOCK

Gary L. White, Linds T. Archer, Beverly K. Beller, and Lerner B. Hinshau

Prepared for Publication

in

Journal of Surgical Research

PRAIRIE S 1918

University of Oklahoma Health Sciences Center Departments of Pathology and Physiology & Biophysics Oklahoma City, Oklahoma

16 February 1978

Reproduction in whole or in part is permitted for any purpose of the United States Covernment

Distribution of this report is unlimited



OFFICE OF NAVAL RESEARCH

Contract N00014-76-C-0229

Project NR 105-516

TECHNICAL REPORT NO. 124

INCREASED SURVIVAL WITH METHYLPREDNISOLONE
POST-TREATMENT IN LETHAL ENDOTOXIN SHOCK

Gary L. White, Linda T. Archer,
Beverly K. Beller, and Lerner B. Hinshaw

Prepared for Publication

in

Journal of Surgical Research

University of Oklahoma Health Sciences Center
Departments of Pathology and Physiology & Biophysics
Oklahoma City, Oklahoma

16 February 1978

Reproduction in whole or in part is permitted for any purpose of the United States Government Distribution of this report is unlimited

ACCESSION FOR

NTIS

DDC

B R Section E

MANNIOUSE D

JI S I ICA TO I

DV

DISTRIBUTION/AVAILABILITY COSES

SPECIAL

The significance of septic shock in man has been emphasized with McCabe's recent reports estimating approximately 132,000 deaths each year in the United States alone (22). Sepsis, also termed endotoxin shock, is one of the most perious forms of shock (20). The significant changes that are occurring with endotoxin shock show progressive malfunctions in most organ systems, including the heart, liver, lung, kidney and brain, associated with depressed hemodynamics and metabolism (5,16,26). Development of an effective therapy for the treatment of septic shock has often been met with failure due to the inability to completely comprehend the various pathophysiologic mechanisms operative in the experimental animal model (18). Many laboratory studies are difficult to evaluate because various anesthetics have been used (15,28,35), and in unanesthetized animal studies the endotoxin is usually administered by bolus injection rather than by slow infusion (15,28,35). Clinical studies are often hard to assess because controlled data from gravely ill patients in different states of the illness in varying clinical settings are reported (23,35).

Numerous experimental studies employing exogenously administered corticosteroids in the therapy of endotoxin shock have been published, and results vary from negligible effectiveness (14,15) to nearly complete protection (9,24,27,30,31,36) against the adverse effects of endotoxin. However, the experimental protocols have been greatly restricted, usually consisting of a bolus injection of endotoxin followed, or preceded, by bolus injections of steroid in the anesthetized animal and in many studies the degree of lethality is not stated. Variations in results may be accounted for by the fact that steroids have been used both as a pretreatment (35) as well as post-treatment (15,28) for shock.

Although a recent clinical study has demonstrated statistically significant protection with steroids against the lethal effects of sepsis (32), the value of corticosteroids for the treatment of septic shock still remains a controversial

issue (28,33,35). Suggested benefits of corticosteroid action in the animal model subjected to endotoxin shock include stimulation of gluconeogenesis (19); decreased pulmonary congestion and pathology (28); preservation of integrity of cellular membranes (37); promotion of adequate tissue perfusion (24); protection of the liver during warm ischemia (9); increased blood flow and elevated arterial blood pressure (15,36); increased cardiac output (30); and augmented muscle, skin and bone blood flows (15). Since studies in endotoxin shock have demonstrated hepatosplanchnic pooling of blood, hypoglycemia (4) and depressed gluconeogenesis (12), it would seem that glucocorticoids reported to stimulate gluconeogenesis, promote tissue perfusion and protect the liver from ischemia, should diminish or abolish the adverse effects of endotoxin. Therefore, the glucocorticoid, methylprednisolone sodium succinate (Solu-Medrol, Upjohn Co.; Kalamazoo, Michigan) was chosen in the present study as a therapeutic regimen for the treatment of endotoxin shock in the canine receiving intravenous LD₁₀₀ of E. coli endotoxin by either slow infusion or bolus injection.

METHODS

Thirty adult mongrel dogs of random sex, selected for freedom of clinical signs of disease, were used in the present study. All dogs were screened for microfilaria of <u>Dirofilaria immitis</u> (heartworms) and eliminated if positive.

Animals were treated for intestinal parasites and allowed a stabilization period of 3-6 weeks; only those with leukocyte counts in the range of 8,000 to 22,000/mm³ and hematocrits exceeding 36% were utilized.

This study was divided into five groups with each group consisting of six dogs. Group I included awake dogs given slow infusions of \underline{E} . \underline{coli} endotoxin (LD₁₀₀) (Difco, Detroit) during a 5-hour period with no therapy. Animals in

Group II were also awake and administered slow infusions of endotoxin (LD $_{100}$) during a 5-hour period with methylprednisolone sodium succinate (MP) post-treatment beginning at +15 minutes after initial infusion of endotoxin. The steroid (MP 50 mg/ml sterile water) was given in a bolus injection of 30 mg/kg at +15 minutes, and a maintenance dose was given via slow infusion starting at +90 minutes over a 120-minute period at a dosage of 15 mg/kg. Group III dogs were anesthetized with sodium pentobarbital, 30 mg/kg, and then administered the LD $_{100}$ dose of endotoxin by slow infusion. This group received MP as administered to Group II. Group IV animals were anesthetized with sodium pentobarbital, then given a bolus injection of endotoxin (LD $_{100}$) and administered MP as in Groups II and III. Group V animals received a bolus injection of endotoxin (LD $_{100}$) after they were anesthetized with sodium pentobarbital but were not treated with methylprednisolone. The LD $_{100}$ of E. coli endotoxin (mean, 2.25 mg/ml) was established by utilizing the survival results from Groups I and V (non-steroid treated endotoxin-shocked animals) in which all dogs died.

A Longdwell indwelling catheter (Beckton-Dickinson; Rutherford, New Jersey) was placed in the external jugular vein of all animals studied and taped in place for collecting blood samples and administering endotoxin and steroid. A special sling was used to support the unanesthetized dogs in a comfortable upright position during the initial 7 hours; afterwards, the dogs were returned to their cages. Dogs living through 7 days post-endotoxin were considered permanent survivors.

Experiments were designed to follow alterations in peripheral white blood cell (WBC) counts, rectal temperature (T_R) , hematocrit (Hct) and blood glucose concentrations, in both treated and non-treated animals. In all groups glucose, WBC, T_R , and Hct were measured initially before endotoxin as well as +15 and +30 minutes after endotoxin, then hourly from +60 through +420 minutes. Blood samples were also collected at +24 hours and +7 days post-endotoxin in surviving animals.

Rectal temperatures were obtained using a Tele-Thermometer probe (Yellow Springs Instruments; Yellow Springs, Ohio). Leukocyte counts were measured with a Coulter Z_F automatic particle counter (Coulter Electronics, Inc.; Hialeah, Fla.). Blood glucose concentrations were determined using a Beckman glucose analyzer (Beckman Instruments, Inc.; Fullerton, Calif.) with an accuracy of ± 3 mg%. Statistics were carried out ulilizing \underline{t} test for paired or unpaired data.

RESULTS

Table 1 shows individual changes in hematocrit in dogs receiving LD $_{100}$ \underline{E} . \underline{coli} endotoxin while Table 3 presents mean values and statistical analysis of the same data. The most marked increases (p<0.02) in hemoconcentration were observed in animals not receiving methylprednisolone (MP) following a slow infusion of endotoxin (Group I, Table 3). Dogs treated with MP after slow infusion of endotoxin (Groups II and III) exhibited significantly lower hematocrit values (P<0.05) when compared with animals administered endotoxin without MP treatment (Groups I and V). Hematocrits also markedly increased (p<0.05) in dogs administered the bolus injections of endotoxin and post-treated with MP (Group IV) compared with animals slow-infused with endotoxin and treated with MP (Group II). Hematocrits remained elevated in two dogs in Group IV that survived through 24 hours but died by 36 hours post-endotoxin administration.

Survival data are shown in Tables 1 and 2. Increased survival rates (83%) were observed in the two groups of animals receiving slow infusions of LD_{100} endotoxin and post-treated with MP (Groups II and III). Of particular interest is the fact that anesthesia did not influence survival results. Animals with the most marked increases in hematocrit did not usually survive. All dogs in Group I died when administered LD_{100} \underline{E} . \underline{coli} endotoxin over a 5-hour infusion period. All six animals in Group IV receiving a bolus injection of LD_{100} endotoxin died even

though they were post-treated with methylprednisolone. The mortality rate was 100% for Group V after LD_{100} bolus in the absence of treatment with methylprednisolone.

Alterations in blood glucose concentration in individual animals in response to LD₁₀₀ endotoxin are arrayed in Table 2 while mean values with statistical evaluations are shown in Table 4. The individual values in Table 2 reveal that hypoglycemia progressively developed in Groups I and V in which methylprednisolone was not administered and in Group IV animals receiving bolus endotoxin with MP treatment. In Groups II, III and IV administered MP a significant hyperglycemia was seen approximately 30 to 120 minutes post-endotoxin (p<0.05) (Table 4). Group V animals given bolus injections of endotoxin but no steroid developed hyperglycemia at 240 to 300 minutes post-endotoxin (p<0.01) compared with all groups treated with MP (Group II, III and IV). Blood glucose values were significantly higher (p<0.05) as late as 7 hours after endotoxin in Group III animals given MP compared with animals in Group I not receiving methylprednisolone.

Changes in rectal temperature are listed in Table 5. The control temperatures for Groups IV and V were significantly higher (p<0.05) than those for Groups I and II, apparently due to random sampling. Groups I through IV showed significant febrile responses after administration of endotoxin by either slow infusion or bolus injection in both awake and anesthetized dogs. In Group V the only significant increase of rectal temperature occurred at 360 minutes with only two dogs surviving at that time.

Table 6 presents alterations in peripheral leukocyte concentration after administration of endotoxin. Endotoxin injection caused a significant leukopenia in all five groups (p<0.05) at 15 through 60 minutes when compared to control values. The levels of leukopenia for Groups IV and V receiving endotoxin by bolus injection were lower (p<0.05) than in the slow-infused groups (Groups I, II and III).

A significant leukocytosis (p<0.01) was observed at 24 hours in Groups II and III in which 83% of all animals survived.

DISCUSSION

Corticosteroid therapy in the treatment of septic shock is still a controversial subject among both clinicians and medical scientists (35). Many laboratory studies are difficult to evaluate because they involve either pretreatment (use of drugs prior to administration of endotoxin) or multiple treatment with bolus injections of endotoxin in contrast to slow infusions (15,28,35).

The primary purpose of this study was to determine the effectiveness of intravenous administration of methylprednisolone sodium succinate (MP) as a post-treatment for canine endotoxin shock. Shock was produced in awake and anesthetized dogs via either bolus injections or 5-hour infusions of LD_{100} \underline{E} . \underline{coli} endotoxin. Results clearly demonstrate an increased survival (83%) with MP post-treatment alone during slow infusion of endotoxin. In contrast, all dogs post-treated with MP died when endotoxin was administered as a bolus. Schumer's double-blind study of patients in sepsis documented increased survival with methylprednisolone (32) which is corroborated by the present studies using a slow infusion model. Thomas and Brockman found that post-treatment with methylprednisolone did not alter survival results in dogs administered intravenous bolus endotoxin (35). Following injection of MP (30 mg/kg) at 1 and 7 hours after bolus injection of LD_{50-60} \underline{E} . \underline{coli} endotoxin, survival time was lengthened (48 hours) in dogs subjected to endotoxin shock (28). Results from the present study clearly indicate that the most appropriate procedure possessing clinical relevance is the endotoxin slow infused model.

Previous work from this laboratory using LD₈₀ endotoxin in dogs with MP posttreatment revealed only a 47% increase in survival rate (15); MP was injected intravenously +15 minutes after endotoxin at a dose of 20 mg/kg body weight with no maintenance doses of the steroid utilized. The half-life of MP has been reported to be approximately 3-4 hours (8); therefore, in the present study a maintenance dose of 15 mg/kg body weight was infused for a 2-hour period beginning 90 minutes after the onset of endotoxin infusion and 75 minutes following the initial 30 mg/kg injection of methylprednisolone. The additional administration of MP may have influenced survival by maintaining its plasma concentration at effective levels during and following administration of endotoxin.

A controversy currently exists over the use of anesthetics in animal shock models. Data from the present study clearly document that use of sodium pentobarbital (30 mg/kg body weight) as an anesthetic agent does not influence survival results. Both groups of animals receiving MP after slow infusion of LD₁₀₀ endotoxin had an 83% survival rate although six dogs were anesthetized and six animals were awake.

Hematocrit increased markedly (p<0.05) in all groups; however, Group II and III animals post-treated with MP showed significantly less hemoconcentration. The degree of hemoconcentration was presumably an important factor in determining mortality. The decreased hematocrits seen in surviving animals could be attributed to the steroid's action in preserving the integrity of cell membranes (37), promotion of tissue perfusion (24), increased blood flow, and elevated blood pressure (15,36). Prager et al has previously demonstrated that dogs given steroids required less fluid to maintain systemic arterial pressure and urine output (28).

Normoglycemia was associated with survival of animals in Groups II and III receiving a lethal slow infusion of endotoxin followed by treatment with methylprednisolone. The presence of normoglycemia suggests a stimulating effect of methylprednisolone on hepatic gluconeogenesis (19) possibly through promotion of adequate hepatic perfusion (9,24). An increased mesenteric blood flow in endotoxinshocked dogs post-treated with methylprednisolone has been reported (36). In a

and the second second

study of rabbits subjected to 30-minute portal vein occlusions producing liver ischemia, 90% of the animals died, while with MP post-treatment only 56% died (9). Animals in Groups I, IV and V all became hypoglycemic during this study and all dogs died in these three groups. Hypoglycemia has been previously associated with death in canine endotoxin shock (1,4,18) and in man during septic shock (29). A positive correlation has been previously established between maintained blood glucose levels and survival in dogs subjected to endotoxin shock (18). Therefore, the action of methylprednisolone on the liver may have been an important factor determining survival in the present study.

The early leukopenia observed in all groups after initiation of either slow infusion or bolus injection of endotoxin was similar to previous results reported by this laboratory (17) as well as those of other investigators (2,3,31). The initial leukopenia was more severe in the two groups receiving bolus injections of endotoxin. Mulholland and Cluff reported that endotoxin causes granulocytes to adhere to the capillary endothelial cells and then later leave the circulation and move into the tissue (25). The return of the leukocyte count to near normal or to a leukocytotic state corroborates earlier studies and may be the result of entry of new leukocytes from the bone marrow into the circulation (10,13,17). Leukocytosis has also been reported to occur after corticosteroid injection (6), and this mechanism might account for some degree of the leukocytosis seen in the survivors. The leukocytosis seen in the animals infused with LD₁₀₀ endotoxin and treated with steroid was similar to but more marked than that observed in dogs given sublethal endotoxin as previously reported (33,39,40).

Elevated temperatures occurred in all groups except Group V. Although the mechanisms for the pyrogenic response to endotoxin are not clearly identified, studies have shown that the neutrophil can release a pyrogen which will produce

a febrile response in animals administered endotoxin (11). There is also evidence that endotoxin produces fever by direct action upon the brain (10). A recent hypothesized mechanism is that hyperthermia may be due to inhibition of Protaglandin E₂ catabolism in the hypothalmus (34). Corticosteroids have been reported to reduce leukocyte pyrogen production (7); however, the groups receiving corticosteroid in this study still exhibited fevers. This may have been due to an overwhelming quantity of endotoxin resulting in excessive pyrogen versus antipyrogenic activity of the corticosteroid. The absence of an elevated temperature in Group V may be the result of the lethal bolus injections of endotoxin producing a poor tissue perfusion, thus negating any pyrexia from pyrogen release.

SUMMARY

The use of corticosteroids has long been intensively studied for the treatment of septic slock; however, there still remains much controversy over their use. This study was designed to determine the therapeutic value of post-treatment with methylprednisolone sodium succinate (MP) in the awake and anesthetized canine receiving LD₁₀₀ of E. coli endotoxin by either intravenous slow infusion or bolus injection. The MP was administered initially at 15 minutes post-endotoxin at a 30 mg/kg body weight dose and then followed at 90 minutes with a maintenance dose of 15 mg/kg by slow infusion over a 120-minute period. It was found that posttreatment with MP produced a significant increase (83%) in survival in dogs receiving LD₁₀₀ E. coli endotoxin (2.25 mg/kg) by slow infusion whether awake or sodium pentobarbital anesthetized. Both the 5-hour infusion and bolus injection of the endotoxin (2.25 mg/kg) produced a 100% mortality with no post-treatment. Post-treatment with the MP did not alter the 100% mortality in the canine bolusinjected endotoxin shock model. Survival was associated with a normoglycemia and stabilized hematocrit, while death was accompanied by hypoglycemia and severe hemoconcentration.

REFERENCES

- 1. Archer, L. T. Hypoglycemia in conscious dogs in live Escherichia coli septicemia: A chronic study. Circ. Shock 3: 93, 1976.
- 2. Atkins, E. Pathogenesis of fever. Physiol. Rev. 40: 580-646, 1960.
- 3. Bennet, I. L. Jr., Cluff, L. E. Bacterial pyrogens. Pharm. Rev. 9: 427-475, 1957.
- Berk, J. L., Hagen, J. F., Beyer, W. M., et al. Hypoglycemia of shock.
 Ann. Surg. 171: 400, 1970.
- 5. Berry, L. J. Metabolic effects of bacterial endotoxins. In: Microbial Toxins, Vol. V (S. Kadis, G. Weinbaum, and S. J. Ajl, eds.), Academic Press, New York, 1971, p. 165.
- 6. Dale, D. C., Fauci, A. S., Guerry, D., et al. Comparison of agents producing a neutrophilic leukocytosis in man: hydrocortisone, prednisone, endotoxin, and etiocholanolone. <u>J. Clin. Invest.</u> 56: 808-813, 1975.
- Dillard, G. M., Bodel, P. Studies on steroid fever II. Pyrogenic and antipyrogenic activity in-vitro of some endogenous steroids of man. <u>J. Clin.</u> Invest. 49: 2418-2426, 1970.
- 8. DiSanto, A. R. The Upjohn Company. Personal Communication.
- Delpin, E. S., Figueoroa, I., Lopez, R., et al. Protective effect of steroids on liver ischemia. <u>Amer. Surgeon</u> 683, 1975.
- 10. Freedman, H. H. Further studies on passive transfer of tolerance to pyrogenicity of bacterial endotoxin. The febrile and leukopenic responses.

 J. Exptl. Med. 112: 619, 1960.
- 11. Gillman, S. M., Bornstein, D. L., and Wood, W. B., Jr. Studies on the pathogenesis of fever. J. Exptl. Med. 114: 729, 1961.
- 12. Groves, A. C., Woolf, L. I., O'Regan, P. J., et al. Impaired gluconeogenesis in dogs with E. coli bacteremia. Surgery 76: 533, 1974.

- 13. Herion, J. C., Walker, R. I., Herring, W. B., and Palmer, J. G. Effects of endotoxin and nitrogen mustard on leukocyte kinetics. Blood 25: 522, 1965.
- 14. Hinshaw, L. B. Shock tour symposium. J. Okla. State Med. Assoc. 59: 477, 1966.
- 15. Hinshaw, L. B., Solomon, L. A., Freeny, P. C., et al. Endotoxin shock: Hemodynamic and survival effects of methylprednisolone. <u>Arch. Surg.</u> 94: 61, 1967.
- 16. Hinshaw, L. B. Belease of vasoactive agents and the vascular effects of endotoxin. In: <u>Microbial Toxins</u>, Vol. V (S. Kadis, G. Weinbaum, and S. J. Ajl, eds.), Academic Press, New York, 1971, p. 209.
- 17. Hinshaw, L. B., Mathis, M. C., Naneato, J. A., and Holmes, D. D. Recovery patterns and lethal manifestations of live <u>E. coli organism shock</u>. <u>J. Trauma</u> 10: 787-794, 1970.
- 18. Hinshaw, L. I., Peyton, M. D., Archer, L. T., et al. Prevention of death in endotoxin shock by glucose administration. Surg. Gynec. Obstet. 139: 851, 1974.
- 19. Holtzman, S., Schuler, J., Earnest, W., et al. Carbohydrate metabolism during endotoxemia. Circ. Shock 1: 99, 1974.
- Lees, N. W. The diagnosis and treatment of endotoxic shock. <u>Anesthesia</u>
 897, 1976.
- 21. Lillehei, R. C., MacLean, L. D. The intestinal factor in irreversible endotoxin shock. Ann. Surg. 148: 573-525, 1958.
- 22. McCabe, W. R. Gram-negative bacteremia. Adv. Intern. Med. 19: 135, 1974.
- 23. McHenry, M. C., and Hawk, W. A. Bacteremia caused by gram-negative bacilli.

 Med. Clin. N. Am. 58: 623, 1974.
- 24. Motsay, G. J., Alho, A., Jaeger, T., et al. Effects of corticosteroids on the circulation in shock: Experimental and clinical results. <u>Fed. Proc.</u> 29: 1861, 1970.
- 25. Mulholland, J. H., and Cluff, L. E. The effect of endotoxin upon susceptibility to infection: The role of the granulocyte. In: <u>Bacterial Endotoxins</u>.

 A Symposium. Quinn & Boden Co., New Jersey, 1964, p. 211.

- 26. Nagler, A. L., and Levenson, S. M. Experimental hemorrhagic and endotoxin shock. In: <u>Microbial Toxins</u>, Vol. V, Academic Press, New York, 1971, p. 341.
- 27. Pitcairn, M., Schuler, J., Erve, P. R., et al. Glucocorticoid and antibiotic effect on experimental gram-negative bacteremic shock. <u>Arch. Surg.</u> 110: 1012, 1975.
- 28. Prager, R., Kirsh, M. M., Dunn, E., et al. The benefits of corticosteroids in endotoxic shock. Ann. Thor. Surg. 19: 142, 1975.
- 29. Rackwitz, R., Jahrmarker, H., Prechtel, K., et al. Hypoglykamie wahrend kreislaufshock. Klin. Wochenschr. 52: 605, 1974.
- 30. Sambhi, M. P., Weil, M. H., and Udhoji, U. H. Acute pharmacodynamic effects of glucocorticoids: cardiac output and related hemodynamic changes in normal subjects and patients in shock. <u>Circulation</u> 31: 523, 1965.
- Schuler, J. J., Erve, P. R., and Schumer, W. Glucocorticoid effect on hepatic carbohydrate metabolism in the endotoxin-shocked monkey. <u>Ann. Surg.</u> 183: 345, 1976.
- 32. Schumer, W. Steroids in the treatment of clinical septic shock. <u>Ann. Surg.</u> 184: 333, 1976.
- Sladen, A. Methylprednisolone: Pharmacologic doses in shock lung syndrome.
 J. Thor. Cardiovasc. Surg. 71: 800, 1976.
- 34. Splawinski, J. A. Mediation of hyperthermia by Prostaglandin E₂: A new hypothesis. Arch. Pharm. 297: S95-S97, 1977.
- 35. Thomas, C. S., and Brockman, S. K. The role of adrenal corticosteroid therapy in Escherichia coli endotoxin shock. Surg. Gynec. Obstet. 126: 61, 1968.
- 36. Vaughn, D., Kirschbaum, T., Bersentes, T., et al. Effects of corticosteroid hormones on regional circulation in endotoxin shock. <u>Proc. Soc. Exptl. Biol.</u> <u>Med.</u> 124: 760, 1967.

- 37. Weissman, G. Labilization and stabilization of lysosomes. Fed. Proc. 53: 1038, 1964.
- 38. White, G. L., Archer, L. T., Schroeder, T., et al. Development of a new model for the study of endotoxin shock. Physiologist 19: 409, 1976.
- 39. White, G. L., Archer, L., Beller, B., et al. Leukocyte response, liver function and altered survival in superlethal endotoxin shock. Fed. Proc. 36: 503, 1977.
- 40. White, G. L., Archer, L. T., Beller, B. K., et al. Leukocyte response and hypoglycemia in superlethal endotoxin shock. <u>Circ. Shock</u>, in press.

TABLE 1. CHANGES IN HEMATOCRIT IN DOGS ADMINISTERED AN LD 100 E. COLID ENDOTOXIN

					Tim	Time, minutes	sa				hours	days	
Dog no.	Control	+15	+30	09+	+120	+180	+240	+300	+360	+420	+24	+1	Fate
Group I:		logs, sl	Awake dogs, slow infusion	ion endo	endotoxin ^C -	no treatment	nent						
-2	36	8 8	50	25	65	8 *	02	89	88	•		:	Died
e	49	49	8	23	15	88	2	64	99	83	*		Died
4	40	7	43	54	5	65	75	*					Died
ro d	49	22	23	23	63	79.5	80	65	29	72	* :		Died
•	7	20	00	/6		?	6	8	†	8			Daid
Group II:		Awake dogs, slow		infusion endotoxin	otoxin -	steroid	treatment		Ş	9	\$	ç	7
	ç	42	44	49	5	2	3	9 1	24	\$ 6	745	8	rived.
∞	20	48	54	25	28	09	09	52	21	23	20	49	Lived
6	23	22	19	09	63	62	28	26	55	54	49	15	Lived
20	39	41	99	19	72	99	09	54	52	20	**		Died
=	44	5	28	26	22	52	48	47	49	20	45	46	Lived
12	4	49	20	23	47	44	45	42	44	45	45	35	Lived
Group 11	III: Anest	Anesthetized dogs		slow infu	infusion endotoxin	otoxin -	steroid	treatment	ıt				
13	44.5	40	43	44	26	25	54	54	49.5	20	57.5	43	Lived
14	49	44	46.5	48	57	55	54	51	20	52	41.5	45	Lived
15	42.5	38	43	46	20	51	52	55	26	26	58	37	Lived
91	47	43	20	26	19	28	55	54	09	59	43	39	Lived
17	49	45	54	68.5	9/	70	69	67	29	89	**		Died
18	47	46	47	48	48	20	48	47	47	46	44	39.5	Lived

TABLE 1 (Con't.)

	4				Time	Time, minutes	es				hours	days	
Dog no.	Dog no. Control	+15	+30	09+	+120	+180	+240	+300	+360	+420	+24	+	Fate
Group IV:		Anesthetized dogs,		us injec	bolus injection endotoxin	lotoxin	- steroid	d treatment	ent				
19	4	42.5	4,	51	65	63	99	29	ר	*			Died
20	51.5	58.5	19	69	7	72	73	74.5	*				Died
2	45	43	43	48	09	62	64	64	65	63	**		Died
22	20	55	53	22	62	63	9	63	99	89	**		Died
23	47	45	42	48	49	20	49	48	47	47	64	***	Died
24	20	25	51.5	55.5	82	62	64	19	09	28	62.5	***	Died
Group V:		Anesthetized dogs, b	dogs, bolus		injection endotoxin	otoxin -	no treat	treatment					
52	42	41	40	46	48	20	48	46	46	47			Died
56	45	42	42	46	20	55	09	09	*				Died
27	42	41	41.5	46	46	9	1	*					Died
88	26	5	99	64	99	72	73	2	2	69	#		Died
53	48	5	22	23	62	64	65	29	*				Died
30	39	48	48	20	25	22	26	22	*				Died

^aMicro hematocrit in percent

^bLD₁₀₀ - mean 2.25 mg/kg <u>E</u>. coli endotoxin

Slow infusion given intravenously over a 5 hour period

dpost treated with 30 mg/kg methylprednisolone sodium succinate by bolus injection at 15 minutes after endotoxin injection then a slow infusion of 15 mg/kg methylprednisolone at 90 minutes post-endotoxin for a 120 minute period

*Anesthetized with sodium pentobarbital 30 mg/kg

Bolus injection given intravenously over a 2 minute period

*Death occurred within 60 minutes of previous sample

**Death occurred between 420 minutes and 24 hours

***Death occurred between 24 and 36 hours

TABLE 2.. ALTERATIONS IN BLOOD GLUCOSE CONCENTRATION IN DOGS ADMINISTERED AN LD100 OF E. COLI ENDOTOXIN

	Fate		Died	Died	Died	Died	חומת		Lived	Lived	Lived	Died	Lived	Lived		Lived	Lived	Lived	Lived	Died	Lived
days	+1					,			112	120	8		101	103		88	011	109	96		96
hours	+24			*		* *			8	140	120	**	108	74		86	103	102	154	*	82
	+420		•	25		19	5		99	107	107	23	88	82		28	8	115	83	101	85
	+360		33	25		67	8		78	96	136	53	75	80	it	28	94	104	83	121	73
	+300		39	54	*	90	6	٠.	75	90	112	41	91	79	treatment	9/	97	105	79	109	75
S	+240	lent	26	6	39	8 2	2	creatment	6	109	120	51	80	90	steroid	87	==	115	83	140	80
Time, minutes	+180	no treatment	55 *	25	29	65	5	steroid t	66	111	118	55	106	80	toxin -	106	117	113	80	901	92
Time	+120	1	8 04	19	8	<u>8</u>	5	endotoxin - s	153	123	144	に	103	93	slow infusion endotoxin	142	144	128	98	94	105
	09+	usion endotoxin ^C	136	84	116	75	96	ion endo	168	136	132	106	120	110	low infu	122	205	104	131	93	26
	+30	w infus	88	2	103	62	2	" infus	165	93	144	108	6	109	dogs, s	180	185	130	130	127	119
	+15	Awake dogs, slow inf	87	88	101	74	6	dogs, slow inf	110	86	113	87	95	100	Anesthetized	101	108	66	93	106	96
	Control	Awake do	00 82	101	8	77	8	Awake (109	26	104	35	107	103		89	94	96	82	102	6
	Dog no. (Group I:	-2	6	+	ر د د		Group II:	1	&	6	2	=	12	Group III:	13	14	15	91	17	18

TABLE 2 (Con't.)

	4				Time	Time, minutes	S				hours	days	
Dog no.	Control	+15	+30	09+	+120	+180	+240	+300	+360	+450	+24	+1	Fate
Group IV:		Anesthetized dogs,	dogs, bolu	s injec	bolus injection endotoxin	lotoxin -	steroic	steroid treatment	ent				
	66	104	145	156	124	8	80	43	26	*			Died
0	6	115	105	107	75	11	89	92	*				Died
	8	142	145	173	102	65	22	26	48	20	**		Died
~	88	126	104	207	164	109	66	85	82	79	**		Died
	108	140	103	137	123	8	6	85	29	65	78	***	Died
24	100	134	141	158	126	6	83	82	88	79	38	***	Died
Group V:	Anesthe	tized o	Anesthetized dogs, bolus		injection endotoxin		no treat	treatment					
	86	179	146	119	85	48	49	44	4	9	*		Died
	80	123	86	84	84	09	38	35	*				Died
1	16	126	140	101	101	48	20	*					Died
28	85	82	89	102	104	65	99	53	89	83	**		Died
6	92	115	105	142	94	18	5	52	*				Died
	106	137	83	901	93	62	33	15	*				Died

^aBlood glucose in mgm percent

^bLD100 - mean 2.25 mg/kg <u>E. coli</u> endotoxin

Slow infusion given intravenously over a 5 hour period

dpost treated with 30 mg/kg methylprednisolone sodium succinate by bolus injection at 15 minutes after endotoxin injection then a slow infusion of 15 mg/kg methylprednisolone at 90 minutes post-endotoxin for a 120 minute period

*Anesthetized with sodium pentobarbital 30 mg/kg

Folus injection given intravenously over a 2 minute period

*Death occurred within 60 minutes of previous sample

**Death occurred between 420 minutes and 24 hours

***Death occurred between 24 and 36 hours

* TABLE 3. ALTERATIONS IN HEMATOCRIT (%) IN DOGS ADMINISTERED ENDOTOXIN (MEAN + SE)

					1	Time, minutes	tes				hours	days
	Control	+15	+30	09+	+120	+180	+240	+300	+360	+420	+24	+
Group 1b	45(2) 47(2)	47(2)	50(2)	56(1)	64(2)	(1)89	69(2)	(1)99	(1)99	(8(3)	-	-
Group II	45(2)	48(2)	54(3)	56(2)	58(4)	56(3)	53(3)	50(2)	50(2)	50(1)	46(2)	44(3)
Group III	47(1)	43(1)	47(2)	52(4)	58(4)	57(3)	55(3)	55(3)	55(3) .025	55(3) .05	49(4)	41(1)
Group IV	47(2)	49(2)	49(3)	55(3)	61(3)	62(3)	64(3)	63(4)	62(4)	59(4) .05	63(1)	•
or bd	45(3)	46(2)	47(3)	51(3)	54(3) .0 5	(6)09	62(4)	60(4)	58(12)	58(11)	+	•

Total of 30 dogs, 6 in each group. All groups were injected with LD₁₀₀ (mean 2.25 mg/kg) E. coli endotoxin

bGroup I: awake dogs, slow infusion endotoxin - no treatment; Group II: awake dogs, slow infusion endotoxin methylprednisolone post-treatment; Group III: anesthetized dogs, slow infusion endotoxin - methylprednisolone
post-treatment; Group IV: anesthetized dogs, bolus injection endotoxin - methylprednisolone post-treatment;
Group V: anesthetized dogs, bolus endotoxin injection - no treatment (see Methods for details)

CInitial measurement for each dog before endotoxin

 $\mathbf{d} \mathbf{p} = \mathbf{unpaired} \text{ comparison to Group I}$

p = unpaired comparison to Group II

fo of 6 animals died

TABLE 4. CHANGES IN BLOOD GLUCOSE CONCENTRATIONS (MGK) IN DOGS ADMINISTERED ENDOTOXIN (MEAN + SE)

					Tim	Time, minutes	es				hours	days
	Control	+15	+30	09+	+120	+180	+240	+300	+360	+420	+54	+1
group I ^b	92 (5)	84	88 (5)	(11)	75 (9)	(5)	(9)	55 (6)	56 (8)	9(1)	•	•
Group II	102	≘€	118 (12) .05	(9) (9) (9)	(9) (9) (05)	95 (13) .02	93 (10) .025	(10)	82 (14)	(13)	105	<u>5</u>
Group III	(3)	<u>5</u> (2)	145	125	8(9) (0)	2 <u>6</u> .	.00 .00 .00	96 (9) (9)	89 (9) 30.	88.60.	108	65
Group IV	(4)	120.	124 (9)	156 (14) .01	119 (21)	88	84 (6) .02	74 (8)	(9)	(7)	(20)	u
Group V	(4)	128 (13) .02	êÊ.	108	93	(5)	48 (5)	34 (7)	(14)	(2)	۵	ø

a,b,c_{See} Table 3

d p = unpaired comparison to Group I

e of 6 animals died

TABLE 5. RESPONSES IN RECTAL TEMPERATURE (°C) IN DOGS ADMINISTERED ENDOTOXIN (MEAN + SE)ª

					1.	Time, minutes	tes				hours	days
	Control	+15	+30	09+	+120	+180	+240	+300	+360	+450	+24	+1
Group Ib	37.8	38.2 (.1)	38.6 (.2)	38.9	39.2 (.5) .025	39.7 (5.3) 2005	39.8 (.2) .001	39.7 (.3)	39.5 (.3)	39.2	•	•
Group II	37.8 (.i)	38.8	38.9 (.2) .005	39.0	38.8	38.9	39.3 (.4)	39.2 (.4) .025	38.9 (.4)	38.7	4	•
Group III	38.0	38.5	38.8	38.8	39.0	39.1 (.3) .025	39.1 (.3) .05	39.3 (.4)	39.6 (.5) .025	39.7 (.4)	38.3	37.9
Group IV	38.1	38.8 (.2)	39.0 (.2) .02	39.1	39.3	39.4 (.5)	39.7	39.9 (.6) .05	39.8	39.6	38.1	æ
Group V	38.3	38.3	37.8 (.4)	38.1	37.9	38.1	38.3	38.6	39.9 (.4) .025	39.7	a	O

a,b,c_{See} Table 3

d p = paired comparison to Control values

e of 6 animals died

fs of 6 animals lived through 7 days but rectal temperature was not measured

TABLE 6. VARIATIONS IN LEUKOCYTE COUNTS (/mm³) IN DOGS ADMINISTERED ENDOTOXIN (MEAN + SE)ª

					Tim	Time, minutes	Sa				hours	days
	Control	+15	+30	09+	+120	+180	+240	+300	+360	+420	+24	+1
Group Ib	12800	960 0 (2500) .0 5	5100 (500) 10.	6000 (500) .00 5	7900	8800 (2200)	8600 (1900)	14600 (4800)	13900	12900	a	ø
Group II	15500 (1400)	6700 (1900) (1900)	8700 (1900) .005	7000 (1000) .005	7500 (1500) .005	10200 (2100)	9000 (1800) .01	14500 (2800)	17100 (4000)	16300 (2700)	41300 (6200)	19700
Group III	12600 (800)	8400 (1200)	5200 (900) .001	4800 (900)	5100 (1000) .005	10100 (2300)	7300 (1800) .05	13500	16800 (4200)	19500 (4500)	54600 (9500) .001	2060 0 (6100)
Group IV	13500	2900 (400)	3900 (500)	4800 (300)	7000 (600) .005	13000	12800	21600 (2800)	19500	17400 (3600)	20600	ø
V duona	14500 (2600)	2400 (200)	3800 (400)	5400 (800)	7500	(200)	10700	11400 (2300)	12500	13800 (2400)	a	۵

a,b,c_{See} Table 3

d p = paired comparison to Control values

e of 6 animals died

Security Classification DOCUMENT CONTROL DATA - R & D Security classification of title, body of abstract and indexing annotation must be entered when the overall report is classified) ORIGINATING ACTIVITY (Corporate author) 28. REPORT SECURITY CLASSIFICATION UNCLASSIFIED UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER OKLAHOMA CITY, OKLAHOMA UNCLASSIFIED INCREASED SURVIVAL WITH METHYLPREDNISOLONE POST-TREATMENT IN LETHAL ENDOTOX IN SHOCK . t and inclusive dates) OR(S) (First name, middle ini ial, last name) Archer, B. K. Beller NO. OF REFS 16 Feb 40 **9**78 NØØØ14-76-C-Ø229 NR 105-516 OTHER REPORT NO(S) (Any other numbers that may be assigned this report) 10. DISTRIBUTION STATEMENT Distribution of this report is unlimited. 12. SPONSORING MILITARY ACTIVITY 11. SUPPLEMENTARY NOTES Office of Naval Research The use of corticosteroids has long been intensively studied for the treatment of septic shock; however, there still remains much controversy over their use. This study was designed to determine the therapeutic value of post-treatment with methylprednisolone sodium succinate (MP) in the awake and anesthetized canine

The use of corticosteroids has long been intensively studied for the treatment of septic shock; however, there still remains much controversy over their use. This study was designed to determine the therapeutic value of post-treatment with methylprednisolone sodium succinate (MP) in the awake and anesthetized canine receiving LD_{100} of E . coli endotoxin by either intravenous slow infusion or bolus injection. The MP was administered initially at 15 minutes post-endotoxin at a 30 mg/kg body weight dose and then followed at 90 minutes with a maintenance dose of 15 mg/kg by slow infusion over a 120-minute period. It was found that post-treatment with MP produced a significant increase (83%) in survival in dogs receiving LD_{100} E. coli endotoxin (2.25 mg/kg) by slow infusion whether awake or sodium pentobarbital anesthetized. Both the 5-hour infusion and bolus injection of the endotoxin (2.25 mg/kg) produced a 100% mortality with no post-treatment. Post-treatment with the MP did not alter the 100% mortality in the canine bolus-injected endotoxin shock model. Survival was associated with a normoglycemia and stabilized hematocrit, while death was accompanied by hypoglycemia and severe hemoconcentration.

1

DD . FORM .. 1473

S/N 0101-807-6811

(PAGE 1)

407464

UNCLASSIFIED
Security Classification

A-31406